ESC 2021: PRONOUNCE Fails to Differentiate Cardiovascular Risk of Degarelix Versus Leuprolide for Prostate Cancer Patients With Cardiovascular Disease
Early enrollment termination and other study limitations hamper interpretation of findings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.